IL10 and neoplasm: Through the JAK-STAT pathway (specifically STAT3), IL-10 signaling inhibits dendritic cell maturation, reduces pro-inflammatory cytokine production by macrophages and other cells, and attenuates T-cell activation, thereby effectively suppressing anti-tumor immunity.